vardenafil chemical structure
Find information on thousands of medical conditions and prescription drugs.

Levitra

Vardenafil (Levitra) is a PDE5 inhibitor used in the treatment of erectile dysfunction. It can assist men with this disorder in achieving and maintaining an erection during sexual activity. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

As a PDE5 inhibitor, vardenafil is closely related in both function and marketing to sildenafil and tadalafil; it has a relatively short effective time, comparable to sildenafil.

History

Vardenafil was co-marketed by Bayer Pharmaceuticals and GlaxoSmithKline (GSK) under the trade name Levitra. As of 2005, the co-promotion rights of GSK on Levitra have been "transferred back" to Bayer in many markets outside of the United States. In Italy, Bayer markets the product as Levitra and GSK markets the product as Vivanza. Due to European Union trade rules, Parallel Imports made result in the Vivanza branded packs being seen alongside Levitra packs in pharmacies in other EU member states.

Clinical use

Main page: PDE5 inhibitor

Indications and contraindications are as for other PDE5 inhibitors.

Adverse drug reactions

More common adverse drug reactions (ADRs) are as per other PDE5 inhibitors and are listed on that page.

Common vardenafil-specific ADRs include: nausea. Infrequent ADRs include: abdominal pain, back pain, photosensitivity, abnormal vision, eye pain, facial oedema, hypertension, palpitation, tachycardia, arthralgia, myalgia, rash, itch, priapism. (Rossi, 2004)

Dose forms

It is available in 2.5 mg, 5 mg, 10 mg, and 20 mg doses in round orange tablets. The normal starting dose is 10 mg (roughly equivalent to 50 mg of sildenafil). Vardenafil should be taken 25-60 minutes prior to sexual activity, with a maximum dose frequency of once per day.

In some territories, such as the UK, only certain doses may be available, i.e. 5 mg, 10 mg, and 20 mg.

Reference

  • Rossi S (Ed.) (2004). Australian Medicines Handbook 2004. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-4-2

Read more at Wikipedia.org


[List your site here Free!]


Atazanavir : new recommendations if combined with tenofovir —and warning on Viagra, Cialis, and Levitra
From AIDS Treatment News, 3/26/04

On March 19, 2004 the FDA notified the public of new prescribing information and precautions for atazanavir (brand name Reyataz), if taken in combination with tenofovir (Viread)--and warned of risks with Viagra or similar drugs.

If atazanavir is taken with tenofovir, the blood level of atazanavir is decreased. Therefore it is now recommended that a small dose of ritonavir be taken in addition, to raise the blood level of atazanavir to compensate. All three drugs are taken together once per day, with food.

Also, Reyataz increases the blood level of Viread, which could increase its side effects. As a precaution, patients combining the drugs should be monitored for tenofovir side effects.

The new Patient Information flyer also warns that if atazanavir is combined with Viagra, Cialis, or Levitra, it could increase the risk of serious side effects of those drugs. Patients are advised not to combine atazanavir with any of these drugs unless their doctor tells them it is OK.

For more information see the new prescribing information for atazanavir, which will be posted at http://www.reyataz.com (we did not find it on the site on April 14). Also see the Patient Information flyer, which may be posted at the end of the prescribing information.

COPYRIGHT 2004 John S. James
COPYRIGHT 2004 Gale Group

Return to Levitra
Home Contact Resources Exchange Links ebay